Plant Name: Peltogyne pubescens
Taxonomic Information:
Plant ID: NPO11910
Plant Latin Name: Peltogyne pubescens
Taxonomy Genus: Peltogyne
Taxonomy Family: Fabaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; NPSR1; | |
| BLM; ALOX12; HSD17B2; HSD17B10; NOX4; AOX1; POLB; | |
| AURKB; PIM1; MET; FLT3; CDK1; EGFR; AXL; KDR; IGF1R; | |
| CA2; CA12; CA7; CA4; | |
| ESR1; ESR2; | |
| ESRRB; ESRRA; | |
| TYR; | |
| MMP12; | |
| AHR; HIF1A; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
| Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.667E-09 | 4.551E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.077E-08 | 1.804E-05 | CA12, CA2, CA4, CA7 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.444E-08 | 2.096E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 4.687E-08 | 4.437E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.264E-07 | 1.692E-04 | ALOX12, AOX1, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.527E-07 | 2.191E-04 | CA12, CA2, CA4, CA7 |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 5.530E-07 | 2.562E-04 | AHR, ESR1, ESR2, ESRRA, ESRRB, PIM1 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.628E-07 | 3.316E-04 | BLM, CA12, CA2, CA4, CA7, ESR1, ESR2, ESRRA, ESRRB, MMP12 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.033E-06 | 3.749E-04 | CA12, CA2, CA4, CA7 |
| MF | Unclassified; | GO:0004872; receptor activity | 1.054E-06 | 3.763E-04 | AHR, AXL, EGFR, ESR1, ESR2, ESRRA, ESRRB, FLT3, IGF1R, KDR, MET, NPSR1, TSHR |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 2.173E-06 | 6.530E-04 | BLM, CYP1A1, CYP1B1, EGFR, ESR1, FLT3, NOX4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.818E-06 | 7.968E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.007E-06 | 8.395E-04 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 4.099E-06 | 1.026E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C9, ESR1, HSD17B2 |
| BP | GO:0022414; reproductive process | GO:0001892; embryonic placenta development | 5.565E-06 | 1.317E-03 | EGFR, ESRRB, HIF1A |
| BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 7.302E-06 | 1.595E-03 | AURKB, BLM, EGFR, HIF1A, NOX4, POLB, TYR |
| BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 8.393E-06 | 1.810E-03 | CDK1, ESR1, ESR2, ESRRA, ESRRB |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.614E-06 | 1.821E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 8.614E-06 | 1.821E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.012E-06 | 1.869E-03 | CA2, CA7 |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 9.382E-06 | 1.927E-03 | AXL, CDK1, EGFR, FLT3 |
| BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 9.873E-06 | 1.991E-03 | ALOX12, EGFR, HIF1A, IGF1R, KDR, MET, NOX4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.534E-05 | 2.760E-03 | ESR1, ESR2, ESRRA, ESRRB |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.800E-05 | 2.993E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.800E-05 | 2.993E-03 | ESR1, ESR2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.800E-05 | 2.993E-03 | CYP1A2, CYP2C9 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.387E-05 | 3.821E-03 | AHR, HIF1A, KDR |
| BP | GO:0008152; metabolic process | GO:1903580; positive regulation of ATP metabolic process | 2.872E-05 | 4.408E-03 | CDK1, ESRRB, HIF1A |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.491E-05 | 6.392E-03 | CYP1A2, CYP2C9 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 4.911E-05 | 6.769E-03 | AURKB, CDK1, CYP1A1, NOX4, POLB |
| BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 4.982E-05 | 6.823E-03 | AXL, FLT3, HIF1A, POLB |
| BP | GO:0009987; cellular process | GO:0001961; positive regulation of cytokine-mediated signaling pathway | 5.860E-05 | 7.781E-03 | AXL, HIF1A, MMP12 |
| BP | GO:0032501; multicellular organismal process | GO:0007435; salivary gland morphogenesis | 6.281E-05 | 8.189E-03 | EGFR, POLB |
| MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 6.281E-05 | 8.189E-03 | FLT3, KDR |
| MF | GO:0098772; molecular function regulator | GO:0030235; nitric-oxide synthase regulator activity | 6.281E-05 | 8.189E-03 | EGFR, ESR1 |
| BP | GO:0050896; response to stimulus | GO:0032355; response to estradiol | 6.463E-05 | 8.377E-03 | CYP1A2, EGFR, ESR1, ESRRA |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 7.663E-05 | 9.534E-03 | EGFR, IGF1R, KDR |
| BP | GO:0009987; cellular process | GO:0043401; steroid hormone mediated signaling pathway | 7.768E-05 | 9.610E-03 | ESR1, ESR2, ESRRA, ESRRB |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.592E-19 | 5.029E-17 | CA12, CA1, CA3, CA2, CA5A, CA4, CA7, CA6, CA9, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 2.841E-13 | 2.756E-11 | CAMK2B, SRC, MMP2, PIK3R1, HIF1A, ESR1, MMP9, PTK2, EGFR, IGF1R, KDR, AKT1, MAPK1, TP53, MET |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 4.250E-12 | 2.749E-10 | GSK3B, FLT3, DAPK1, MMP2, PIK3R1, HIF1A, MMP9, EGFR, NFKB1, PTK2, IGF1R, AR, ABL1, AKT1, MAPK1, MET, TP53, PPARD |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.934E-10 | 1.915E-08 | CYP2C9, APP, CYP2C8, CYP2D6, MAOA, ALOX5, ALOX15, MAPK1, ALOX12, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.235E-09 | 3.422E-08 | GSK3B, AR, AKT1, MAPK1, PIK3R1, TP53, EGFR, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 1.005E-09 | 3.251E-08 | CAMK2B, GSK3B, SRC, ABL1, AKT1, MAPK1, PIK3R1, EGFR, PTK2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.476E-09 | 3.579E-08 | CYP2C9, CYP2C8, PLA2G1B, ALOX5, ALOX15, TBXAS1, ALOX12, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.556E-10 | 7.547E-09 | CYP2C9, CYP2C8, PLA2G1B, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 3.216E-09 | 5.672E-08 | SRC, MMP2, AKT1, MAPK1, PIK3R1, ESR1, MMP9, EGFR, ESR2 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 7.442E-09 | 1.031E-07 | PLA2G1B, MAOA, ALOX15, AKR1B1, ALOX12, PYGL, CYP2C19, CYP3A4, CYP19A1, HSD17B10, HSD17B1, ALOX5, HSD17B2, CD38, AOX1, XDH, MGAM, GAA, TYR, CYP2C9, CYP2C8, TBXAS1, CYP1A2, CYP1A1, ALPI |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.784E-09 | 5.402E-08 | FLT3, AKT1, MAPK1, PIK3R1, TP53, MET, HIF1A, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.126E-09 | 4.582E-08 | DAPK1, SRC, MMP2, MAPK1, MMP9, TP53, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 4.997E-09 | 7.457E-08 | GSK3B, SRC, AKT1, MAPK1, PIK3R1, ESR1, NFKB1, ESR2 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 3.538E-09 | 5.719E-08 | CYP2C9, CYP2C8, MAOA, CYP2D6, CYP1A2, AOX1, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 9.075E-09 | 1.174E-07 | HSD17B1, ALOX5, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 2.329E-08 | 2.824E-07 | FLT3, PIM1, AKT1, MAPK1, PIK3R1, NFKB1, PPARD |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 5.919E-08 | 6.379E-07 | CAMK2B, AKT1, MAPK1, PIK3R1, TP53, EGFR, IGF1R |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.449E-07 | 1.339E-06 | GSK3B, SRC, KDR, AKT1, MAPK1, PIK3R1, MET, PTK2, EGFR, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 8.647E-08 | 8.829E-07 | CAMK2B, AKT1, MAPK1, PIK3R1, HIF1A, EGFR, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 3.205E-07 | 2.487E-06 | GSK3B, KDR, AKT1, MAPK1, PIK3R1, PKN1, TP53, MET, PTK2, EGFR, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.101E-07 | 1.068E-06 | AKT1, MAPK1, PIK3R1, TP53, MET, EGFR, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.637E-08 | 3.009E-07 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.489E-07 | 2.195E-06 | GSK3B, SRC, AKT1, MAPK1, PIK3R1, TP53, ESR1, HIF1A |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 2.833E-07 | 2.390E-06 | CAMK2B, GSK3B, ABL1, AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 4.269E-07 | 3.067E-06 | PLA2G1B, KDR, ABL1, AKT1, MAPK1, PIK3R1, MET, EGFR, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 5.772E-07 | 3.862E-06 | FLT3, MMP3, TP53, MPO, MMP9, MET, NFKB1, PTK2, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 6.235E-07 | 4.032E-06 | GSK3B, AKT1, MAPK1, PIK3R1, PPARA, TP53, EGFR, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 1.265E-06 | 7.671E-06 | SRC, AKT1, MAPK1, STAT6, PIK3R1, TP53, MMP9, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.998E-07 | 2.424E-06 | CYP2C9, CYP2C8, CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 3.586E-07 | 2.676E-06 | GSK3B, AKT1, MAPK1, PIK3R1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 5.620E-07 | 3.862E-06 | ALK, AKT1, MAPK1, PIK3R1, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 4.814E-06 | 2.395E-05 | ABCC1, PIM1, ABL1, CYP1B1, MAPK1, TP53, MMP9, MET, EGFR, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 9.403E-07 | 5.885E-06 | SRC, KDR, AKT1, MAPK1, PIK3R1, PTK2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04062 | Chemokine signaling pathway | 7.976E-06 | 3.868E-05 | GSK3B, CXCR1, SRC, AKT1, MAPK1, PIK3R1, NFKB1, PTK2 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.505E-06 | 8.590E-06 | AKT1, MAPK1, PIK3R1, TP53, EGFR, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.096E-05 | 5.064E-05 | PARP1, LMNA, AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.399E-05 | 6.312E-05 | GSK3B, CSNK2A1, CDK1, AKT1, CD38, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 2.736E-06 | 1.434E-05 | ABL1, AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 9.067E-06 | 4.290E-05 | GSK3B, CSNK2A1, AKT1, RAB9A, PIK3R1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.917E-05 | 8.264E-05 | SRC, KDR, AKT1, MAPK1, PIK3R1, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.802E-05 | 7.947E-05 | MMP2, PIM1, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.375E-06 | 8.081E-06 | CYP2C9, CYP2C8, CYP1A2, CYP1A1, AOX1, CYP3A4 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.964E-06 | 1.513E-05 | CSNK2A1, SRC, MAPK1, MET, EGFR, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.736E-06 | 1.434E-05 | CYP2C9, CYP2D6, CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 2.781E-05 | 1.148E-04 | GSK3B, AKT1, PIK3R1, PYGL, PPARA, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 2.929E-05 | 1.160E-04 | MMP3, AKT1, MAPK1, PIK3R1, MMP9, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.037E-04 | 3.659E-04 | CAMK2B, AKT1, MAPK1, PIK3R1, PPARA, NFKB1, TSHR |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.248E-04 | 4.247E-04 | POLB, SRC, CDK1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 4.782E-05 | 1.750E-04 | ABCC1, AKT1, MAPK1, PIK3R1, TP53, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.217E-04 | 4.216E-04 | GSK3B, ESRRB, AKT1, MAPK1, PIK3R1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 2.178E-04 | 6.761E-04 | THPO, PIM1, AKT1, AOX1, STAT6, PIK3R1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 2.178E-04 | 6.761E-04 | CAMK2B, SRC, CD38, MAPK1, PIK3R1, EGFR |
| 09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 4.692E-05 | 1.750E-04 | GSK3B, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 2.119E-05 | 8.937E-05 | GSK3B, AKT1, MAPK1, PIK3R1, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.907E-04 | 6.165E-04 | CDK1, AKT1, MAPK1, PIK3R1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 2.877E-05 | 1.160E-04 | AKT1, MAPK1, PIK3R1, MET, HIF1A |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 1.345E-04 | 4.500E-04 | CAMK2B, SRC, MMP2, MAPK1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 1.029E-04 | 3.659E-04 | AKT1, PIK3R1, TP53, NFKB1, PTK2 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.568E-04 | 5.155E-04 | AKT1, PIK3R1, TP53, NFKB1, IGF1R |
| 09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05010 | Alzheimer's disease | 3.031E-04 | 8.910E-04 | BACE1, APP, GSK3B, MAPK1, MAPT, HSD17B10 |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 2.196E-04 | 6.761E-04 | AKT1, MAPK1, PIK3R1, HIF1A, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 3.327E-05 | 1.291E-04 | CXCR1, SRC, MET, EGFR, NFKB1 |
| 09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 2.517E-04 | 7.629E-04 | GSK3B, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 4.102E-05 | 1.561E-04 | SLCO1B1, CA2, SLCO1B3, CYP3A4, ABCG2 |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 5.254E-04 | 1.456E-03 | SRC, TBXAS1, AKT1, MAPK1, PIK3R1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.368E-06 | 1.312E-05 | MAOA, CYP1A2, CYP1A1, AOX1, CYP1B1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 4.511E-04 | 1.268E-03 | ALOX5, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04114 | Oocyte meiosis | 5.453E-04 | 1.490E-03 | CAMK2B, AR, CDK1, MAPK1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 7.773E-04 | 2.011E-03 | AKT1, MAPK1, PIK3R1, EGFR, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04728 | Dopaminergic synapse | 6.771E-04 | 1.775E-03 | CAMK2B, GSK3B, MAOA, AKT1, DRD4 |
| 09150 Organismal Systems | 09158 Development | hsa04360 | Axon guidance | 6.308E-04 | 1.676E-03 | GSK3B, ABL1, MAPK1, MET, PTK2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04310 | Wnt signaling pathway | 1.043E-03 | 2.561E-03 | CAMK2B, GSK3B, CSNK2A1, TP53, PPARD |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 1.110E-03 | 2.692E-03 | CXCR1, AKT1, MAPK1, PIK3R1, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04910 | Insulin signaling pathway | 9.480E-04 | 2.358E-03 | GSK3B, AKT1, MAPK1, PIK3R1, PYGL |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | 1.371E-03 | 3.243E-03 | GSK3B, AKT1, PIK3R1, PPARA, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 2.623E-03 | 5.655E-03 | AKT1, MAPK1, MAPT, TP53, EGFR, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05164 | Influenza A | 2.613E-03 | 5.655E-03 | GSK3B, AKT1, MAPK1, PIK3R1, NFKB1 |
| 09140 Cellular Processes | 09141 Transport and catabolism | hsa04144 | Endocytosis | 2.834E-03 | 5.911E-03 | CXCR1, SRC, KDR, MET, EGFR, IGF1R |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 2.780E-03 | 5.911E-03 | POLB, GSK3B, AKT1, PIK3R1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04060 | Cytokine-cytokine receptor interaction | 3.172E-03 | 6.478E-03 | CXCR1, THPO, FLT3, KDR, MET, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05152 | Tuberculosis | 2.812E-03 | 5.911E-03 | CAMK2B, SRC, AKT1, MAPK1, NFKB1 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.968E-03 | 4.545E-03 | CAMK2B, SRC, ALOX12, PIK3R1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04916 | Melanogenesis | 2.119E-03 | 4.835E-03 | CAMK2B, GSK3B, MAPK1, TYR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04922 | Glucagon signaling pathway | 2.197E-03 | 4.956E-03 | CAMK2B, AKT1, PYGL, PPARA |
| 09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 2.619E-03 | 5.655E-03 | AKT1, MAPK1, PIK3R1, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 2.444E-03 | 5.449E-03 | AKT1, MAPK1, PIK3R1, NFKB1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 3.093E-03 | 6.383E-03 | CAMK2B, AKT1, MAPK1, PIK3R1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04540 | Gap junction | 1.324E-03 | 3.170E-03 | SRC, CDK1, MAPK1, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 8.438E-04 | 2.154E-03 | SRC, PIK3R1, MET, PTK2 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04110 | Cell cycle | 4.593E-03 | 9.000E-03 | GSK3B, ABL1, CDK1, TP53 |
| 09150 Organismal Systems | 09151 Immune system | hsa04670 | Leukocyte transendothelial migration | 3.851E-03 | 7.623E-03 | MMP2, PIK3R1, MMP9, PTK2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 3.107E-04 | 8.997E-04 | AKT1, MAPK1, PIK3R1, HIF1A |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 4.226E-04 | 1.206E-03 | SRC, ABL1, MAPK1, NFKB1 |
| 09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 5.024E-03 | 9.746E-03 | AKT1, PIK3R1, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 3.448E-03 | 6.896E-03 | AKT1, PIK3R1, TSHR |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00500 | Starch and sucrose metabolism | 3.448E-03 | 6.896E-03 | MGAM, GAA, PYGL |
| 09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 1.843E-03 | 4.307E-03 | MGAM, AKT1, PIK3R1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 5.591E-04 | 1.506E-03 | MGAM, GAA, AKR1B1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00350 | Tyrosine metabolism | 8.838E-04 | 2.227E-03 | MAOA, AOX1, TYR |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.859E-04 | 8.532E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; TYR; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; EGFR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; EGFR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; EGFR; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; EGFR; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR; |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
| NA: NA | HIV infections | NA | AHR; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; EGFR; |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; EGFR; |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; EGFR; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; EGFR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; KDR; FLT3; HIF1A; EGFR; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; TYR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| NA: NA | Edema | NA | CA2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; ESRRA; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
